GC LabCell, which came out of a merger between the cell therapy division of GC and the cord blood storage division of GCLabs, focuses on its strategic tasks of researching and developing natural killer (NK) cell-based immunotherapy agents and stem cell-based treatments for rare diseases.
The company plans to expand its business into development of more diverse stem cell-based treatments and a comprehensive range of healthcare services for the global market.